ClinicalTrials.gg
CompletedNCT06497699Updated Sep 3, 2025Results posted

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

A Phase 4 interventional study of Dexycu in Inflammation and Cataract, sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd. Completed at 2 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Primary conditionCataractRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cataract
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Cataract.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Oct 2021, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
263
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
6th of 34
263 · median 50
Started
2021
with 6 others
Phase 4
18 of 34
none open now
Registered
31st of 34
by date
Lead sponsor
2 of 34
Ocumension Therapeutics (Shanghai) Co., Ltd

Among the 34 studies testing dexamethasone in Cataract, this one is the 6th largest by enrollment, is one of 7 that started in 2021, is one of 18 in phase 4, and was the 31st registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.

Read the detailed description

To evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts in real-world clinical settings, medical history and follow-up data from 113 subjects of Dexycu group and 150 subjects of external control group will be prospectively collected in Hainan, China. Additionally, questionnaires will be collected from surgeons on 30 cases to evaluate the difficulty, duration and safety of the Dexycu injector.

03

Conditions studied

  • Inflammation
  • Cataract

Browse trials for

Keywords

  • Cataract Surgery
  • Postoperative Inflammation
04

In context

Cataract Reclassified

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

This study's enrollment of 263 is above the median of 79 across 1,094 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Ocumension Therapeutics (Shanghai) Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Cataract, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be able to understand and sign the form and be able to follow the study procedures.
  • Male or female subjects over 40 years of age who are scheduled to undergo cataract phacoemulsification surgery combined with intraocular lens implantation.

Exclusion criteria

Exclusion Criteria:

  • Known to dexamethasone or any component of the Dexycu.
  • History of intraocular inflammation of any cause in either eye, presence of corneal abnormalities or malnutrition.
  • Have high intraocular pressure, with an IOP(intraocular pressure) of > 21 mmHg in the test eye at screening, regardless of whether receiving anti-glaucoma monotherapy therapy.
  • Posterior capsule rupture or lens dislocation, anterior vitreal membrane rupture, vitreous prolapse and intraoperative floppy iris syndrome during cataract surgery.
  • Other conditions that the investigator considers inappropriate to participate the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Study Group

    Single injection of DEXYCU in the treatment eye after cataract surgery.

    Drug: Dexycu

  • No intervention
    Control Group

    The clinical routine treatment after cataract surgery was adopted without intervention

Interventions

  • DrugDexycu

    single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone

07

What researchers measure

Primary outcomes

  1. Anterior Chamber Cell Clearing Rate

    The primary outcome is to compare the ratio of subjects with anterior chamber cell grade 0 at day 8 after cataract surgery of both Dexycu group and external control group. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).

    Time frame: DAY 8

08

Results

Posted Sep 3, 2025

Participant flow

113 recruited to the study group treat with DEXYCU postsurgerically. 150 recruited to control group which observation study was conducted.

Participant flow — Overall Study
MilestoneControl GroupStudy Group
Started150113
Completed143110
Not completed73

Outcome measures

PrimaryAnterior Chamber Cell Clearing Rate

The primary outcome is to compare the ratio of subjects with anterior chamber cell grade 0 at day 8 after cataract surgery of both Dexycu group and external control group. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).

Time frame:
DAY 8
Reported as:
Count of participants · Participants
Anterior Chamber Cell Clearing Rate
ParticipantsControl GroupStudy Group
Anterior Chamber Cell Clearing Rate11995

Adverse events

Collected over Through study completion, an average of 90 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group0/150 (0%)5/150 (3.3%)14/150 (9.3%)
Study Group1/113 (0.9%)1/113 (0.9%)15/113 (13.3%)
Most frequent serious events
Most frequent serious events
EventControl GroupStudy Group
Macular OedemaEye disorders4/1500/113
EndophthalmitisEye disorders0/1501/113
DiplopiaEye disorders1/1500/113
Most frequent other events
Most frequent other events
EventControl GroupStudy Group
Corneal endothelial cell lossEye disorders14/15015/113

Baseline characteristics

Age, Customized
Age, Customized(Participants)Control GroupStudy GroupTotal
< = 60 years151732
> 60 years13596231
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupStudy GroupTotal
Female8455139
Male6658124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control GroupStudy GroupTotal
American Indian or Alaska Native000
Asian150113263
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Control GroupStudy GroupTotal
China149113262
09

Study locations

2 sites
  • Hainan Traditional Chinese Medicine Hospital
    Haikou, Hainan, China
  • Boao Super Hospital
    Bo'ao, China
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2023, 20 months.

Results were first posted in Sep 2025, 2 years 1 month after primary completion.

Of 46 phase 4 interventional studies under Cataract, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jul 12, 2024
StartActual
Oct 28, 2021
Primary completionActual
Jul 8, 2023
CompletionActual
Dec 14, 2023
Results first posted
Sep 3, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06497699
Lead sponsor
Ocumension Therapeutics (Shanghai) Co., Ltd
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
Oct 28, 2021
Primary completion
Jul 8, 2023
Completion
Dec 14, 2023
Results posted
Sep 3, 2025
Last update
Sep 3, 2025

Study contacts

Zhixun Li
study director · Ocumension Therapeutics (Shanghai) Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion